These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34510321)

  • 1. Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
    Rubio-Tomás T
    Mol Biol Rep; 2021 Nov; 48(11):7499-7508. PubMed ID: 34510321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functions of SMYD proteins in biological processes: What do we know? An updated review.
    Rueda-Robles A; Audano M; Álvarez-Mercado AI; Rubio-Tomás T
    Arch Biochem Biophys; 2021 Nov; 712():109040. PubMed ID: 34555372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
    Yi X; Jiang XJ; Fang ZM
    Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases.
    Padilla A; Manganaro JF; Huesgen L; Roess DA; Brown MA; Crans DC
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
    Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
    Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
    Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
    J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
    Xu S; Zhong C; Zhang T; Ding J
    J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
    Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system.
    Rubio-Tomás T
    Heliyon; 2021 Jun; 7(6):e07387. PubMed ID: 34235289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
    Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
    Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
    Chandramouli B; Chillemi G
    J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
    Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
    J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.
    Oliveira-Santos W; Rabello DA; Lucena-Araujo AR; de Oliveira FM; Rego EM; Pittella Silva F; Saldanha-Araujo F
    Tumour Biol; 2016 Jul; 37(7):9473-81. PubMed ID: 26790435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
    Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
    J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
    Chandra P; Dixit R; Pratap A; Mishra S; Mishra R; Shukla VK
    Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):111-117. PubMed ID: 33994736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
    Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
    Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
    Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation.
    Su H; Meng C; Xu J; Su Z; Xiao C; Yang D
    Cell Death Dis; 2022 Oct; 13(10):890. PubMed ID: 36270984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
    Zhu CL; Huang Q
    Dig Dis Sci; 2020 Feb; 65(2):489-499. PubMed ID: 31441002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.